- Home
- BUD vs REGN Comparison
BUD vs REGN Comparison
Compare BUD & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUD
- REGN
- Stock Information
- Founded
- BUD 1366
- REGN 1988
- Country
- BUD Belgium
- REGN United States
- Employees
- BUD N/A
- REGN N/A
- Industry
- BUD Beverages (Production/Distribution)
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- BUD Consumer Staples
- REGN Health Care
- Exchange
- BUD Nasdaq
- REGN Nasdaq
- Market Cap
- BUD 96.4B
- REGN 110.0B
- IPO Year
- BUD N/A
- REGN 1991
- Fundamental
- Price
- BUD $63.05
- REGN $707.51
- Analyst Decision
- BUD Buy
- REGN Buy
- Analyst Count
- BUD 3
- REGN 26
- Target Price
- BUD $64.00
- REGN $996.00
- AVG Volume (30 Days)
- BUD 2.4M
- REGN 867.9K
- Earning Date
- BUD 02-26-2025
- REGN 05-01-2025
- Dividend Yield
- BUD 1.66%
- REGN 0.12%
- EPS Growth
- BUD 10.00
- REGN 10.27
- EPS
- BUD 2.86
- REGN 38.34
- Revenue
- BUD $59,768,000,000.00
- REGN $14,202,000,000.00
- Revenue This Year
- BUD $0.91
- REGN $4.68
- Revenue Next Year
- BUD $4.69
- REGN $5.51
- P/E Ratio
- BUD $21.34
- REGN $18.45
- Revenue Growth
- BUD 0.65
- REGN 8.27
- 52 Week Low
- BUD $45.94
- REGN $642.00
- 52 Week High
- BUD $67.49
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- BUD 90.26
- REGN 54.29
- Support Level
- BUD $61.75
- REGN $672.50
- Resistance Level
- BUD $60.33
- REGN $739.00
- Average True Range (ATR)
- BUD 0.79
- REGN 19.86
- MACD
- BUD 0.77
- REGN 1.28
- Stochastic Oscillator
- BUD 96.71
- REGN 52.65
About BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, according to Euromonitor, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 it acquired SABMiller.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).